{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:51:25Z","timestamp":1789480285846,"version":"build-2803163510"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>This study reports a case of cold agglutinin disease (CAD) secondary to lymphoplasmacytic lymphoma in a patient intolerant to rituximab plus bendamustine and with persistent uncontrolled hemolysis following zanubrutinib therapy. The addition of the complement C3 inhibitor iptacopan to a cyclophosphamide and dexamethasone regimen successfully controlled hemolysis and improved hemoglobin levels. Within one week of treatment, the patient achieved transfusion independence, with hemoglobin increasing from 67 g\/L to 90 g\/L by week 3 and 101 g\/L by week 7, alongside normalized bilirubin levels and no adverse events. The follow-up period was 4 months, during which the patient showed sustained remission. These findings suggest that iptacopan can rapidly ameliorate hemolysis in CAD, warranting further investigation into its therapeutic potential.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1672590","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T05:29:41Z","timestamp":1759469381000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Iptacopan for cold agglutinin disease: a case report with literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Baozhi","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiudan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzhi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingen","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangsheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2033982","article-title":"Autoimmune hemolytic anemias","volume":"385","author":"Berentsen","year":"2021","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41572-024-00566-2","article-title":"Autoimmune haemolytic anaemias","volume":"10","author":"Michel","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa2308695","article-title":"Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria","volume":"390","author":"Peffault de Latour","year":"2024","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9123859","article-title":"New insights in autoimmune hemolytic anemia: from pathogenesis to therapy stage 1","volume":"9","author":"Barcellini","year":"2020","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(18)30922-7","article-title":"Serum sickness","volume":"3","author":"Buhner","year":"1985","journal-title":"Dermatol Clin"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3597","article-title":"Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients","volume":"103","author":"Berentsen","year":"2004","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005674","article-title":"Cold agglutinin disease revisited: a multinational, observational study of 232 patients","volume":"136","author":"Berentsen","year":"2020","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-778175","article-title":"Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial","volume":"130","author":"Berentsen","year":"2017","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012039","article-title":"Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease\/cold agglutinin syndrome","volume":"138","author":"Jalink","year":"2021","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-835413","article-title":"Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024190","article-title":"Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial","volume":"2","author":"R\u00f6th","year":"2018","journal-title":"Blood Adv"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in cold agglutinin disease","volume":"384","author":"R\u00f6th","year":"2021","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014955","article-title":"Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial","volume":"140","author":"R\u00f6th","year":"2022","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2025.102938","article-title":"Pegcetacoplan for the treatment of warm autoimmune hemolytic anemia: a case report","author":"Gavriilaki","year":"2025","journal-title":"Blood Cells Mol Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood.2023022549","article-title":"Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia","volume":"145","author":"Roman","year":"2025","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(25)00081-X","article-title":"Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors","volume":"12","author":"Risitano","year":"2025","journal-title":"Lancet Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in igA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.04.029","article-title":"Design and rationale of the APPELHUS phase 3 open-label study of factor B inhibitor iptacopan for atypical hemolytic uremic syndrome","volume":"8","author":"Kavanagh","year":"2023","journal-title":"Kidney Int Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1672590\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T05:29:41Z","timestamp":1759469381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1672590\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":18,"alternative-id":["10.3389\/fimmu.2025.1672590"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1672590","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"article-number":"1672590"}}